{"transactions":[{"id":941806,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:13.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":690900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":690900,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":690900},"source":{"system":"sec-edgar","filing":"0001213900-26-002950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390026002950/ownership.xml","form_type":"4"}},{"id":1127185,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:08:19.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":9326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."}],"balance_after":9326,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9326},"source":{"system":"sec-edgar","filing":"0001213900-25-050128","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390025050128/ownership.xml","form_type":"4"}},{"id":1219031,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T16:16:13.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":17923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":17923,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":17923},"source":{"system":"sec-edgar","filing":"0001213900-25-021188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390025021188/ownership.xml","form_type":"4"}},{"id":1242436,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T17:57:17.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares."}],"balance_after":255000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-25-017510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390025017510/ownership.xml","form_type":"4"}},{"id":1342474,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T21:11:53.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares."}],"balance_after":127500,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-24-105727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390024105727/ownership.xml","form_type":"4"}},{"id":1510458,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T16:00:23.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":1387,"price":1.683,"value":2334.321,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":3117,"source":{"system":"sec-edgar","filing":"0000950170-24-061597","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000095017024061597/ownership.xml","form_type":"4"}},{"id":1559212,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:24:57.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001213900-24-026815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390024026815/ownership.xml","form_type":"4"}},{"id":1628028,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-21T17:02:32.000Z","date":"2024-02-19","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of February 19, 2024 (the \"Vesting Commencement Date\"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":40000,"derivative":{"exercise_price":11.32,"expiration_date":"2034-02-18","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-24-003680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919124003680/doc4.xml","form_type":"4"}},{"id":1738604,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-16T17:26:42.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":4524,"price":0.4973,"value":2249.7852,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":43271,"source":{"system":"sec-edgar","filing":"0001209191-23-055554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919123055554/doc4.xml","form_type":"4"}},{"id":1890975,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-16T08:01:44.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":4863,"price":0.459,"value":2232.117,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":38747,"source":{"system":"sec-edgar","filing":"0001209191-23-029643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919123029643/doc4.xml","form_type":"4"}},{"id":2050395,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:02:10.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 17, 2023 (the \"Vesting Commencement Date\"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":500000,"derivative":{"exercise_price":0.47,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-004044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919123004044/doc4.xml","form_type":"4"}},{"id":2114059,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-11-16T18:30:54.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":4651,"price":0.4684,"value":2178.5284,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":33884,"source":{"system":"sec-edgar","filing":"0001209191-22-057381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919122057381/doc4.xml","form_type":"4"}},{"id":2223735,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T16:17:27.000Z","date":"2022-06-20","kind":"grant","acquired":true,"shares":235541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 50% on June 20, 2023, and in 12 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":235541,"derivative":{"exercise_price":1.49,"expiration_date":"2032-06-19","underlying":"Common Stock","underlying_shares":235541},"source":{"system":"sec-edgar","filing":"0001209191-22-038677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919122038677/doc4.xml","form_type":"4"}},{"id":2240021,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-07T17:30:12.000Z","date":"2022-06-07","kind":"purchase","acquired":true,"shares":25000,"price":1.3305,"value":33262.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.275 to $1.360. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":29233,"source":{"system":"sec-edgar","filing":"0001209191-22-034881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919122034881/doc4.xml","form_type":"4"}},{"id":2267337,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-17T20:46:06.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":4233,"price":1.53,"value":6476.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":4233,"source":{"system":"sec-edgar","filing":"0001209191-22-029892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919122029892/doc4.xml","form_type":"4"}},{"id":2427433,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-24T20:11:43.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":235541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2022 (the \"Vesting Commencement Date\"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":235541,"derivative":{"exercise_price":6.65,"expiration_date":"2032-01-19","underlying":"Common Stock","underlying_shares":235541},"source":{"system":"sec-edgar","filing":"0001209191-22-004687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919122004687/doc4.xml","form_type":"4"}},{"id":2587684,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Earn-out Right","published_at":"2021-08-27T18:01:59.000Z","date":"2021-08-25","kind":"grant","acquired":true,"shares":49790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an \"Earn-Out\" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an \"Earn-Out\" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an \"Earn-Out\" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an \"Earn-Out\" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an \"Earn-Out\" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023."}],"balance_after":49790,"derivative":{"underlying":"Common Stock","underlying_shares":49790},"source":{"system":"sec-edgar","filing":"0001209191-21-053691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919121053691/doc4.xml","form_type":"4"}},{"id":2587683,"issuer":{"id":89916,"kind":"organization","name":"eFFECTOR Therapeutics, Inc.","symbol":"EFTR"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-27T18:01:59.000Z","date":"2021-08-25","kind":"grant","acquired":true,"shares":337997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the \"Merger Agreement\"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. (\"Merger Sub\"), and eFFECTOR Therapeutics, Inc. (\"Old eFFECTOR\"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the \"Merger\"). Upon consummation of the Merger (the \"Effective Time\"), each outstanding option to purchase shares of old eFFECTOR common stock (each an \"old eFFECTOR Option\") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) approximately 0.09657, rounded down to the nearest whole share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests 25% on December 7, 2021, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":337997,"derivative":{"exercise_price":2.39,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":337997},"source":{"system":"sec-edgar","filing":"0001209191-21-053691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000120919121053691/doc4.xml","form_type":"4"}},{"id":4136228,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":70000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 2, 2015, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 2, 2015, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-02","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4136227,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":102300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This Out of the Money Option, which provided vesting in 48 equal monthly installments beginning on January15, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.15, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This Out of the Money Option, which provided vesting in 48 equal monthly installments beginning on January15, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.15, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.15,"expiration_date":"2026-12-14","underlying":"Common Stock","underlying_shares":102300},"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4136226,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 18, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 18, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.76,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4136225,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 20, 2015, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 20, 2015, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.5,"expiration_date":"2024-07-01","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4136224,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":123300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This Out of the Money Option, which provided for vesting in 48 equal monthly installments beginning on February 6, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.98, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Out of the Money Option, which provided for vesting in 48 equal monthly installments beginning on February 6, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.98, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.98,"expiration_date":"2026-01-05","underlying":"Common Stock","underlying_shares":123300},"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4136223,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":1.52,"value":228000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4136222,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-12-11T15:23:23.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":13000,"price":1.52,"value":19760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000089924317028418/doc4.xml","form_type":"4"}},{"id":4367940,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-03-30T17:16:25.000Z","date":"2017-03-29","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.  50% of the RSUs shall vest on December 31, 2017, if the recipient is employed by or providing services to the Issuer on such date, and the remaining 50% of the RSUs shall vest on December 31, 2018, if the recipient is employed by or providing services to the Issuer on such date."}],"balance_after":163000,"source":{"system":"sec-edgar","filing":"0001274644-17-000023","document":"wf-form4_149090857141894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000127464417000023/wf-form4_149090857141894.xml","form_type":"4"}},{"id":4370176,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-03-28T16:06:35.000Z","date":"2017-03-28","kind":"purchase","acquired":true,"shares":3000,"price":1.2848,"value":3854.4,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001274644-17-000016","document":"wf-form4_149073158027908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000127464417000016/wf-form4_149073158027908.xml","form_type":"4"}},{"id":4518629,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-16T16:40:02.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":102300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Option to purchase Common Stock granted by the Issuer pursuant to the Issuer's Fourth Amended and Restated 2011 Stock Option and Incentive Plan (the \"Plan\"), qualified under Rule 16b-3(d)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in 48 equal monthly installments beginning on January 15, 2017, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":102300,"derivative":{"exercise_price":2.15,"expiration_date":"2026-12-14","underlying":"Common Stock","underlying_shares":102300},"source":{"system":"sec-edgar","filing":"0001274644-16-000162","document":"wf-form4_148192438943982.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274644/000127464416000162/wf-form4_148192438943982.xml","form_type":"4"}}]}